



US011028141B2

(12) **United States Patent**
Britton et al.

(10) **Patent No.:** **US 11,028,141 B2**
(45) **Date of Patent:** **Jun. 8, 2021**

(54) **THERAPEUTIC FOR THE PREVENTION
AND/OR TREATMENT OF WEIGHT GAIN
AND/OR DIABETES**

FOREIGN PATENT DOCUMENTS

WO 2008/103751 A2 8/2008
WO 2010/063865 A1 6/2010

(71) Applicant: **Baylor College of Medicine**, Houston,
TX (US)

OTHER PUBLICATIONS

(72) Inventors: **Robert Allen Britton**, Houston, TX
(US); **Catherine Tomaro-Duchesneau**,
Houston, TX (US)

(73) Assignee: **Baylor College of Medicine**, Houston,
TX (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **16/348,443**

(22) PCT Filed: **Nov. 9, 2017**

(86) PCT No.: **PCT/US2017/060809**

§ 371 (c)(1),

(2) Date: **May 8, 2019**

(87) PCT Pub. No.: **WO2018/089602**

PCT Pub. Date: **May 17, 2018**

(65) **Prior Publication Data**

US 2019/0270790 A1 Sep. 5, 2019

Related U.S. Application Data

(60) Provisional application No. 62/419,581, filed on Nov.
9, 2016.

(51) **Int. Cl.**

A61K 38/16 (2006.01)

A61K 38/00 (2006.01)

A61P 1/00 (2006.01)

A61P 3/04 (2006.01)

C07K 14/605 (2006.01)

(52) **U.S. Cl.**

CPC **C07K 14/605** (2013.01); **A61K 38/16**
(2013.01); **A61P 1/00** (2018.01); **A61P 3/04**
(2018.01); **A61K 38/00** (2013.01)

(58) **Field of Classification Search**

CPC . **A61K 38/00**; **A61K 38/16**; **A61P 1/00**; **A61P**
3/04; **C07K 14/605**

USPC **530/308**, **324**; **514/7.2**, **6.9**, **1.1**, **21.3**

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2002/0146701 A1* 10/2002 Hamilton **C07K 14/43595**
435/6.16
2010/0166708 A1* 7/2010 Gallo **A61P 33/00**
424/93.2
2011/0268757 A1 11/2011 Borrás Cuesta et al.
2011/0268787 A1 11/2011 Bollag et al.

Q79MA7 from UniProtKB, pp. 1-5. Integrated in UniProtKB/
TrEMBL on Jul. 5, 2004. (Year: 2004).*

Obesity from Merck Manual, pp. 1-13. Accessed Jun. 2, 2020.
(Year: 2020).*

Diabetes Mellitus (DM) from Merck Manual, pp. 1-14. Accessed
Jun. 2, 2020. (Year: 2020).*

Metabolic Syndrome from Merck Manual, pp. 1-3. Accessed Jun. 2,
2020. (Year: 2020).*

Nonalcoholic Fatty Liver Disease (NAFLD) from Merck Manual,
pp. 1-4. Accessed Jun. 2, 2020. (Year: 2020).*

Short Bowel Syndrome from Merck Manual, pp. 1-2. Accessed Jun.
2, 2020. (Year: 2020).*

Yampolsky et al., "The Exchangeability of Amino Acids in Pro-
teins," Genetics, Aug. 2005, 170: 1459-1472 (Year: 2005).*

Betts et al., "Amino Acid properties and Consequences of Substi-
tutions," Bioinformatics of Geneticists, 2003, John Wiley & Sons,
Ltd., 289-316. (Year: 2003).*

Designing Custom Peptides from Sigma, pp. 1-2. (Year: 2004).*

Schinz et al., The phosphate recognition site of *Escheria coli*
maltodextrin phosphorylase, FEBS, 286 (1,2): 125-128. (Year:
1991).*

Voet et Voet, John Wiley & Sons, Inc., pp. 235-241. (Year: 1995).*

Ngo et al., "Computational Complexity," Protein Structure Predic-
tion, and the Levinthal Paradox, The Protein Folding Problem and
Tertiary Structure Prediction, K. Merc Jr. and S. Le Grand Edition,
pp. 491-495. (Year: 1994).*

Berendsen HJC, "A Glimpse of the Holy Grail?" Science, 282:
642-643. (Year: 1998).*

Bradley et al., "Limits of Cooperativity in a Structurally Modular
Protein: Response of the NOTch Ankyrin Domain to Analogous
Alanine Substitutions in Each Repeat," J. Mol. Biol., 324: 373-386.
(Year: 2002).*

Hogan et al. "Glucagon-like peptide-1 (GLP-1) and the regulation
of human invariant natural killer T cells: lessons from obesity,
diabetes and psoriasis", Diabetologia 54.11 (2011): 2745-2751.

Mittermayer et al. "Addressing unmet medical needs in type 2
diabetes: a narrative review of drugs under development", Current
diabetes reviews 11.1 (2015): 17-31.

Cogen et al. "Staphylococcus epidermidis Antimicrobial d-Toxin
(Phenol-Soluble Modulin-c) Cooperates with Host Antimicrobial
Peptides to Kill Group A Streptococcus", PLoS ONE, Jan. 2010,
vol. 5, Issue 1, e8557.

Sansom et al., "Ion channels formed by amphipathic helical peptides",
Eur Biophys J (1991) 20:229-240.

* cited by examiner

Primary Examiner — Julie Ha

(74) Attorney, Agent, or Firm — Norton Rose Fulbright
US LLP

(57) **ABSTRACT**

Embodiments of the disclosure encompass compositions
and methods for the treatment of medical conditions in
which increases in GLP-1 are beneficial to an individual. In
specific embodiments, the disclosure concerns certain pep-
tides that are capable of inducing GLP-1 production in an
individual with a medical condition, such as type II diabetes
or obesity. In other cases, an individual is not obese or
overweight but is provided the peptide in an effort to reduce
weight from fat.

7 Claims, 15 Drawing Sheets

Specification includes a Sequence Listing.